Brolucizumab

Healio’s top retina/vitreous items this week covered a license agreement between Astellas and 4D Molecular Therapeutics as well as a review of retinal vasculitis or vascular occlusion events following treatment with brolucizumab.

A systematic review of real-world evidence described 70 eyes of 63 patients with retinal vasculitis or vascular occlusion following treatment with brolucizumab for neovascular age-related macular degeneration.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology.

In this Healio Video Perspective, Mathew W. MacCumber, MD, PhD, discusses his poster presentation on brolucizumab treatment from the Retina Society meeting.

Two phase 3 trials, KESTREL and KITE, identified brolucizumab as a viable diabetic macular edema treatment option, according to a study published in the American Journal of Ophthalmology.

Anti-VEGF regimens that include aflibercept, brolucizumab and ranibizumab were ideal in both safety and efficacy in patients with neovascular age-related macular degeneration, according to a study.

WAIKOLOA, Hawaii — Brolucizumab 6 mg demonstrates a favorable benefit-risk profile in the treatment of patients with diabetic macular edema, according to a presentation at Retina 2022.

Patients with diabetic macular edema experienced visual acuity gains and reduced central subfield thickness after 2 years of treatment with Beovu, according to a press release from Novartis.

Applications for Beovu to treat diabetic macular edema have been accepted in the United States, Europe and Japan, according to a press release from Novartis.

In this video, Arshad Khanani, MD, speaks about one of his presentations at the virtual Euretina congress in which he reported the results of an analysis of retinal fluid and visual acuity outcomes in the Archway trial.